Rotaviral infection is the most common gastrointestinal illness of children in the world, affecting both developed and developing economies. There is no specific drug treatment for rotavirus infection. Vaccination and good hygiene are key to prevention.
Approximately 5-10% of the world's population are Lewis histoblood group antigen negative, that percentage is as high as 30% in some African countries. Despite vaccination, the Lewis negative population show a disproportionate prevalence and recurrence of rotavirus infection. However, initial studies have shown that infection with a rotavirus G9P strain may provide improved protection within this group. Inventors have isolated a human rotavirus G9P strain, designated CDC-6, that grows to a high titer with a stable outer structure, making it an ideal vaccine candidate strain. The CDC-6 strain possesses favorable virological and molecular features and may serve as a promising candidate for a new live oral or an inactivated rotavirus vaccine. CDC seeks partners to jointly develop this technology in pre-clinical and clinical testing.
- Novel rotavirus vaccines
- Neonatal/childhood vaccination initiatives
- Large scale antigen production
- Use in diagnostics of rotavirus disease
- Rotavirus surveillance programs, important for both developing and developed nations
- New vaccine candidate option for animals
- Research tool
- Broader population coverage (both the Lewis-positive and negative population)
- Isolated strains are representative of those involved in community-acquired infection
- Suitable for the development of improved, broadly effective rotavirus vaccines; no current vaccine has the P antigen strain
- Potential for a new inactivated injection and/or live oral vaccine format
- May be administered alone or in combination with other vaccines
- First human G9P genotype that can grow to high titer in Vero cells
- Shown to maintain the integrity of triple layered particles during upstream and downstream process